Method for Primary Prevention of Allergic Disorders During Infancy Through IgE-Class-Specific Immunosuppression
The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.
1 - 7 . (canceled)
8 . A method for suppressing production of allergen-specific IgE antibodies in infancy, which includes administration of an anti-IgE antibody at a pharmaceutically effective dose to a pregnant mother and/or a child at any point from after birth to infancy.
9 . A method that suppresses IgE-class-specific immune responses during the fetal stage to infancy, which includes administration of an anti-IgE antibody at a pharmaceutically effective dose to a pregnant mother and/or a child at any point from after birth to infancy.
10 . The method according to claim 8 , wherein the method prevents the onset of allergic disorders in infancy and later.
11 . The method according to claim 8 , wherein the method further includes an additional immunotherapy using an allergen that is administered to the child.
12 . A method for suppressing IgE-class-specific immune responses during the fetal stage to infancy, which includes administration of an anti-IgE antibody at a pharmaceutically effective dose to a pregnant mother and/or a child at any point from after birth to infancy, and it provides the aforementioned method including additional immunotherapy using an allergen that is administered to the child.
13 - 21 . (canceled)